Mailed test kits aim to boost colon cancer screening in underserved brooklyn
NCT ID NCT06269744
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether sending a letter, a home stool test kit (FIT), and follow-up phone calls can increase colorectal cancer screening among 3,000 patients aged 45-75 at community health centers in Brooklyn. Those who respond get help completing the test or scheduling a colonoscopy if needed. The goal is to catch cancer early in a population that often misses screening.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mailed FIT kit and navigation support
- What this could lead to
- If successful, this approach could significantly increase colorectal cancer screening rates in underserved populations, catching cancers earlier and saving lives.
- What could go wrong
- This is a behavioral intervention, not a new drug or cure. Success depends on patient participation and follow-through, and results may not apply to other settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Community Health Care Network of New York
Brooklyn, New York, 11206, United States
-
NYU Langone Health
Brooklyn, New York, 11203, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict who will survive a bowel surgery leak?
- Can a Two-Drug attack shrink Hard-to-Treat colorectal tumors?
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- A mobile app aims to turn health awareness into action — a trial puts it to the test
- Can a walking routine alter cancer biomarkers? new trial investigates
- Web tool aims to empower rare cancer patients in genomic choices